117 related articles for article (PubMed ID: 15531031)
1. Poly-guanosine strings improve cellular uptake and stimulatory activity of phosphodiester CpG oligonucleotides in human leukocytes.
Bartz H; Mendoza Y; Gebker M; Fischborn T; Heeg K; Dalpke A
Vaccine; 2004 Nov; 23(2):148-55. PubMed ID: 15531031
[TBL] [Abstract][Full Text] [Related]
2. Phosphorothioate oligodeoxyribonucleotides induce in vitro proliferation of chicken B-cells.
Wattrang E
Vet Immunol Immunopathol; 2009 Oct; 131(3-4):218-28. PubMed ID: 19447503
[TBL] [Abstract][Full Text] [Related]
3. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
Zhang Z; Guo K; Schluesener HJ
J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory DNA activates production of type I interferons and interleukin-6 in equine peripheral blood mononuclear cells in vitro.
Wattrang E; Berg M; Magnusson M
Vet Immunol Immunopathol; 2005 Sep; 107(3-4):265-79. PubMed ID: 15955566
[TBL] [Abstract][Full Text] [Related]
5. Activation of natural killer-like YT-INDY cells by oligodeoxynucleotides and binding by homologous pattern recognition proteins.
Kaur H; Jaso-Friedmann L; Leary JH; Praveen K; Brahmi Z; Evans DL
Scand J Immunol; 2005 Oct; 62(4):361-70. PubMed ID: 16253123
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo.
Dalpke AH; Zimmermann S; Albrecht I; Heeg K
Immunology; 2002 May; 106(1):102-12. PubMed ID: 11972638
[TBL] [Abstract][Full Text] [Related]
7. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
8. The immunostimulatory activity of phosphorothioate CpG oligonucleotides is affected by distal sequence changes.
Roberts TL; Dunn JA; Sweet MJ; Hume DA; Stacey KJ
Mol Immunol; 2011 Apr; 48(8):1027-34. PubMed ID: 21324527
[TBL] [Abstract][Full Text] [Related]
9. Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides.
Matsuoka N; Nishikawa M; Mohri K; Rattanakiat S; Takakura Y
J Control Release; 2010 Dec; 148(3):311-6. PubMed ID: 20887761
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds.
Macfarlane DE; Manzel L
J Immunol; 1998 Feb; 160(3):1122-31. PubMed ID: 9570525
[TBL] [Abstract][Full Text] [Related]
11. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
[TBL] [Abstract][Full Text] [Related]
12. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells.
Sivori S; Carlomagno S; Moretta L; Moretta A
Eur J Immunol; 2006 Apr; 36(4):961-7. PubMed ID: 16525994
[TBL] [Abstract][Full Text] [Related]
14. CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA.
Yasuda K; Rutz M; Schlatter B; Metzger J; Luppa PB; Schmitz F; Haas T; Heit A; Bauer S; Wagner H
Eur J Immunol; 2006 Feb; 36(2):431-6. PubMed ID: 16421948
[TBL] [Abstract][Full Text] [Related]
15. Uptake, intracellular distribution, and novel binding proteins of immunostimulatory CpG oligodeoxynucleotides in microglial cells.
Zhang Z; Weinschenk T; Schluesener HJ
J Neuroimmunol; 2005 Mar; 160(1-2):32-40. PubMed ID: 15710455
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulatory capacity of DNA vaccine vectors in porcine PBMC: a specific role for CpG-motifs?
Verfaillie T; Cox E; Goddeeris BM
Vet Immunol Immunopathol; 2005 Jan; 103(1-2):141-51. PubMed ID: 15626469
[TBL] [Abstract][Full Text] [Related]
17. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production.
Giordani L; Sanchez M; Libri I; Quaranta MG; Mattioli B; Viora M
J Leukoc Biol; 2009 Aug; 86(2):261-71. PubMed ID: 19401392
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant properties of CpG oligonucleotides in primates.
Verthelyi D
Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
[TBL] [Abstract][Full Text] [Related]
19. Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression.
Griebel PJ; Brownlie R; Manuja A; Nichani A; Mookherjee N; Popowych Y; Mutwiri G; Hecker R; Babiuk LA
Vet Immunol Immunopathol; 2005 Oct; 108(1-2):11-6. PubMed ID: 16098606
[TBL] [Abstract][Full Text] [Related]
20. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
